This inventor holds 4 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Sanofi, Aileron Therapeutics, Inc.. Active years: 2013-2018.
Location History:
- Paris, FR (2015)
- Newton, MA (US) (2013 - 2018)
Company Filing History:
Years Active: 2013-2018
Title: Jiawen Han: Innovator in Antibody Therapeutics
Introduction
Jiawen Han is a prominent inventor based in Newton, MA (US). He has made significant contributions to the field of antibody therapeutics, particularly in the development of antagonistic antibodies targeting Eph receptors. With a total of 4 patents, his work has the potential to impact cancer treatment significantly.
Latest Patents
One of Jiawen Han's latest patents involves EPHA2 receptor antagonist antibodies. These antibodies specifically bind to and inhibit Class A Eph receptors. The invention includes cytotoxic conjugates, pharmaceutical compositions, and kits that comprise these antibodies. The methods of use for these antibodies are particularly noteworthy, as they can antagonize the effects of growth factors on tumor cell growth and survival. This innovation is aimed at treating tumors that express elevated levels of Class A Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, and pancreatic cancer. Additionally, the derivatized antibodies may be utilized in the diagnosis and imaging of such tumors.
Career Highlights
Throughout his career, Jiawen Han has worked with notable companies, including Sanofi and Aileron Therapeutics, Inc. His experience in these organizations has contributed to his expertise in the field of antibody development and cancer therapeutics.
Collaborations
Jiawen has collaborated with several professionals in his field, including Veronique Blanc and Claudia Fromond. These collaborations have likely enriched his research and development efforts.
Conclusion
Jiawen Han is a distinguished inventor whose work in antibody therapeutics holds promise for advancing cancer treatment. His innovative patents and collaborations reflect his commitment to improving healthcare outcomes through scientific research.